共 143 条
[31]
Sands BE(2002)Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial The Lancet 359 1541-1752
[32]
Anderson FH(2009)Predicting factors of fistula healing and clinical remission after infliximab-based combined therapy for perianal fistulizing Crohn’s disease Dig Dis Sci 54 1746-40
[33]
Bernstein CN(2015)Effectiveness of adalimumab in perianal fistulas in crohn’s disease patients naive to anti-TNF therapy J Clin Gastroenterol 49 34-1342
[34]
Colombel JF(2019)Systematic analysis of the impact of diagnostic delay on bowel damage in paediatric versus adult onset Crohn’s disease J Crohns Colitis 13 1334-431
[35]
Sandborn WJ(2003)Response to infliximab is related to disease duration in paediatric Crohn’s disease Aliment Pharmacol Ther 18 425-1125
[36]
Rutgeerts P(2010)Genome-wide meta-analysis increases to 71 the number of confirmed Crohn’s disease susceptibility loci Nat Genet 42 1118-2098
[37]
Biemans VBC(2015)Response to infliximab in Crohn’s disease: genetic analysis supporting expression profile Mediators Inflamm 2015 318207-250
[38]
van der Meulen-de Jong AE(2010)Predictive value of epithelial gene expression profiles for response to infliximab in Crohn’s disease Inflamm Bowel Dis 16 2090-208
[39]
van der Woude CJ(2002)Long-term evolution of disease behavior of Crohn’s disease Inflamm Bowel Dis 8 244-749
[40]
Sandborn WJ(2019)predictors of perianal fistula relapse in Crohn’s disease Inflamm Bowel Dis 63 204-746